Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 8.8% Today

What is Intellia Therapeutics, Inc.?

NTLA is a biotechnology company specializing in gene editing and CRISPR-based treatments. The company has been focusing on innovative therapies targeting hereditary diseases like transthyretin amyloidosis.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 8.8% on Jan 28, 2026 15:05

• NTLA saw a decline in its stock value as the FDA removed the clinical hold on one of its gene therapy trials for ATTRv-PN, causing uncertainty in the market.
• The ongoing hold on the trial for ATTR-CM due to severe side effects and a patient's death added to the pessimism surrounding NTLA.
• Despite the positive development of the FDA allowing the resumption of patient enrollment in one trial, concerns about regulatory issues and safety continued to impact NTLA's stock performance.
• Investors appear cautious about potential safety implications on NTLA's future trials and its ability to handle regulatory hurdles efficiently.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia gets FDA nod to resume one gene therapy trial after safety pause

Intellia Therapeutics announced that the FDA has lifted a clinical hold on one of its late-stage gene therapy trials for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), allowing the company to resume patient enrollment. Shares of Intellia rose 10% on the news. A separate trial for ATTR cardiomyopathy (ATTR-CM) using the same therapy remains on hold following a patient's death due to severe liver-related side effects, and Intellia is working with the FDA on a path forward for that program.

https://www.reuters.com/legal/litigation/us-fda-lifts-clinical-hold-intellias-nerve-disease-trail-2026-01-27/

FDA lifts hold on an Intellia CRISPR drug trial

The FDA has lifted a clinical hold on one of Intellia Therapeutics' Phase 3 trials for its CRISPR-based treatment, nexiguran ziclumeran (nex-z), for transthyretin amyloidosis. This comes after a serious liver toxicity event, including a participant's death, caused regulators to pause two trials last October. The company will implement new risk mitigation measures for the "MAGNITUDE-2" trial, which targets the nerve-affecting form of the disease, but the hold on the "MAGNITUDE" trial for cardiomyopathy patients remains.

https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/

FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program

The FDA has lifted a clinical hold on one of Intellia Therapeutics' gene editing programs, MAGNITUDE-2, for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This decision allowed Intellia's shares to rise by 10% and enables the company to resume patient enrollment for the Phase III trial. The hold was initially placed in October 2025 after a patient death in a related trial, though a hold remains on MAGNITUDE, the sister trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

https://www.biospace.com/fda/fda-lifts-one-of-two-clinical-holds-on-intellias-attr-gene-editing-program

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Trial

Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for ATTRv-PN patients. The company has agreed to enhanced safety monitoring measures and plans to promptly resume patient enrollment and dosing, while also increasing the trial's enrollment target from 50 to 60 patients. Discussions with the FDA are ongoing for the MAGNITUDE trial for ATTR-CM.

https://www.tradingview.com/news/tradingview:af01b6d4e72c6:0-intellia-therapeutics-announces-fda-lift-of-clinical-hold-on-magnitude-2-trial/

FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial

The FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran in patients with ATTRv-PN, which was previously on hold due to a patient death from severe liver toxicity. Intellia plans to resume enrollment and dosing after protocol modifications and enhanced safety monitoring. However, the separate MAGNITUDE Phase 3 trial for ATTR-CM remains on clinical hold, leading to ongoing regulatory uncertainty for a key part of the program.

https://www.tipranks.com/news/company-announcements/fda-lifts-hold-on-intellias-magnitude-2-trial

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 6.3% Today

Ethereum ($ETH) Crypto Forecast: Down 7.3% Today

Pepe ($PEPE) Crypto Forecast: Down 6.2% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 6.0% Today

Stellar ($XLM) Crypto Forecast: Down 7.0% Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.4% Today

Chiliz ($CHZ) Crypto Forecast: Down 12.2% Today

Worldcoin ($WLD) Crypto Forecast: Down 9.6% Today

XRP ($XRP) Crypto Forecast: Down 6.1% Today

Copper ($COPPER) Commodity Forecast: Down 6.1% Today

Intellia Therapeutics, Inc. Price History

06.00.2026 - NTLA Stock was up 6.3%

• The market sentiment towards NTLA has been negative due to a regulatory setback and FDA clinical hold on its main pipeline candidate, as well as mixed Q3 results.
• NTLA experienced a significant bullish movement today because of the inducement grants introduced by the company to recruit new talent.
• This action underscores Intellia's dedication to its goals and likely boosted investor confidence in the company's future, despite recent challenges.

20.00.2026 - NTLA Stock was up 5.0%

• Intellia Therapeutics (NTLA) witnessed a significant bullish movement recently, possibly influenced by ARK Invest's continuous buying and increased position in the company.
• Despite conflicting valuations, investor confidence in Intellia's clinical pipeline and overall market trends has supported the stock's upward trajectory.
• The company's recovery from a previous decline, ongoing progress in clinical trials, and favorable analyst recommendations have all reinforced investor confidence and contributed to the positive market movement.
• ARK's consistent investment in Intellia, despite past stock fluctuations, reflects strong confidence in the company's future prospects and the effectiveness of its CRISPR-based therapy approach.

13.00.2026 - NTLA Stock was up 9.3%

• The bullish movement in NTLA stock can be attributed to positive analyst sentiments and Buy ratings from firms like TD Cowen, UBS, and Barclays, indicating confidence in the company's future performance.
• Despite recent setbacks such as the FDA clinical hold on its lead gene editing trial due to safety concerns, investors may be optimistic about the company's ability to address these issues and move forward with its clinical trials and regulatory plans.
• The upcoming presentation at the J.P. Morgan Healthcare Conference could also be fueling investor optimism, as it provides a platform for the company to showcase its developments and potentially attract more interest from the market.
• The conflicting views on NTLA's valuation, with some considering it undervalued while others pointing out its high Price-to-Sales ratio, highlight the complexity of assessing the stock's true worth and the importance of considering various factors before making investment decisions.

21.00.2026 - NTLA Stock was up 15.0%

• Conflicting valuation signals are evident for the stock, as with a DCF model suggesting undervaluation but a P/S ratio indicating overvaluation compared to industry peers.
• Renewed interest in the stock has been sparked by ARK Investment's increased stake and the upcoming J.P. Morgan Healthcare Conference.
• ARK Invest, led by Cathie Wood, has shown confidence in the company's future prospects by acquiring NTLA shares for three consecutive days.
• Despite positive clinical trial progress and recent gains, the stock's valuation remains a matter of debate among investors and analysts.

08.00.2026 - NTLA Stock was up 5.1%

• The surge in NTLA's stock price may be linked to notable insider purchasing activity by Director Fred Cohen, who acquired 150,000 shares of the company's common stock. This insider buy could have boosted market confidence in the company's future outlook.
• Contrasting Cohen's buying behavior with other insider transactions, which lean towards more sells than buys, might have indicated to investors that the director is optimistic about the company's long-term potential.
• Furthermore, anticipation surrounding the company's participation in the 44th Annual J.P. Morgan Healthcare Conference, where Intellia Therapeutics will discuss its CRISPR-based therapies, could have generated positive investor sentiment and contributed to the stock's bullish movement.
• Overall, a combination of insider buying activities, positive advancements in clinical trials, and involvement in a reputable healthcare conference likely fueled investor optimism, driving the upward momentum in NTLA's stock price.

27.00.2026 - NTLA Stock was up 5.8%

• NTLA stock soared by 10% today in a strong bullish movement.
• A clinical hold on one of Intellia's advanced gene therapy trials for ATTRv-PN was lifted by the FDA, allowing the company to restart patient enrollment.
• The FDA's approval to resume the trial has instilled confidence in Intellia's gene editing initiatives, leading to a notable surge in the stock price.
• Investors are keenly watching for further regulatory decisions on Intellia's clinical trials, especially concerning the ATTR amyloidosis program, which is expected to impact the stock's performance in the near term.

27.00.2026 - NTLA Stock was up 8.2%

• The rise in NTLA's stock price is linked to increased institutional investment from ARK Invest and positive updates on previous clinical hold concerns.
• CEO John Leonard's statement that a patient fatality in the nex-z program was not due to liver toxicity likely reassured investors and hinted at a potential lifting of the FDA hold, bolstering investor confidence.
• The upcoming regulatory decisions on the company's clinical trials, particularly regarding its hereditary angioedema (HAE) candidate, Lonvoguran Ziclumeran, are key points of interest for investors looking at future growth potential.
• Despite uncertainties around its ATTR amyloidosis program and mixed analyst ratings, ARK Invest's recent buying activity demonstrates investor optimism and readiness to handle the volatility often seen with biotech stocks like NTLA.

12.00.2026 - NTLA Stock was down 3.1%

• The recent bearish movement in NTLA could be attributed to the FDA clinical hold on its lead gene editing trial following safety concerns like a patient death and liver enzyme elevations, leading to uncertainty among investors.
• Despite being considered undervalued by some analysts, the high Price-to-Sales (P/S) ratio of 20.4x compared to the industry average of 12.1x raises questions about its true valuation, potentially causing bearish sentiment.
• The conflicting views from different valuation methods and the upcoming presentation at the J.P. Morgan Healthcare Conference might have added to the volatility and uncertainty surrounding NTLA's future prospects, influencing the bearish market movement.
• The insider buying activity by Fred Cohen, acquiring a significant number of shares, could indicate his confidence in the company's long-term potential, contrasting with the broader market sentiment and potentially signaling a divergence in perspectives among investors.

22.00.2026 - NTLA Stock was up 5.8%

• NTLA saw a notable bullish trend today, potentially influenced by several key factors:
• A recent surge in the company's stock price and increased attention from ARK Investment and the J.P. Morgan Healthcare Conference have attracted investor interest.
• Varied signals on valuation, including indications of both undervaluation based on a DCF model and potential overvaluation suggested by a high P/S ratio, may have led to market volatility and trading possibilities.
• The generally optimistic outlook for the gene editing industry, underscored by anticipated market expansion and transformative prospects for genetic disease treatment, may have also bolstered NTLA's bullish movement.
• Investors weighing the risks associated with stock volatility, clinical trial results, and regulatory challenges within the gene editing market could have also contributed to NTLA's market performance.

28.00.2026 - NTLA Stock was down 8.8%

• NTLA saw a decline in its stock value as the FDA removed the clinical hold on one of its gene therapy trials for ATTRv-PN, causing uncertainty in the market.
• The ongoing hold on the trial for ATTR-CM due to severe side effects and a patient's death added to the pessimism surrounding NTLA.
• Despite the positive development of the FDA allowing the resumption of patient enrollment in one trial, concerns about regulatory issues and safety continued to impact NTLA's stock performance.
• Investors appear cautious about potential safety implications on NTLA's future trials and its ability to handle regulatory hurdles efficiently.

16.00.2026 - NTLA Stock was up 6.7%

• Continued buying activity of Intellia Therapeutics (NTLA) stock by a prominent investor totaling approximately $682,000 has boosted investor confidence and pushed the stock price up.
• Despite recent challenges such as regulatory issues and a decline in stock price, Intellia's recovery and positive clinical trial advances have led to a 32% increase in stock value year-to-date, reflecting optimism among investors.
• Initial concerns regarding brokerage ratings and insider selling have been overshadowed by a recent purchasing spree by a notable investor and the company's strong Q3 earnings performance.
• The market's positive response to the ongoing investor confidence and growth potential of Intellia Therapeutics, despite recent obstacles, indicates a bullish trend in the market.

15.00.2026 - NTLA Stock was down 5.0%

• Despite facing safety concerns leading to the halting of Intellia Therapeutics' MAGNITUDE ATTR-CM trial by the FDA, the stock saw a notable surge of 20.7%. This unexpected positive movement could be linked to various factors:
• The market may be responding favorably to the ongoing Phase 3 ionvo-z trial for hereditary angioedema, which is currently fully enrolled and expected to yield results in mid-2026, potentially driving growth.
• The increased acquisition of 92,485 NTLA shares by SG Americas Securities LLC possibly boosted investor confidence, despite recent insider selling activities.
• Analysts expressing optimism about Intellia Therapeutics, with TD Cowen assigning a Buy rating, could have also played a role in the stock's upward trajectory, standing out amidst the general market pessimism.